Ranbaxy tanks again on US govt probe
After rising 15 per cent Wednesday, the Ranbaxy stock resumed its downward journey on reports in the US media that a US Congressional Committee will examine Ranbaxy's drug approvals in the US and potential violations of manufacturing regulations. The committee will also scrutinise the US drug regulator Food and Drug Administration's (FDA's) role in approving products of the Indian drug major.